Summary: Recently, robotic-assisted thoracic surgery (RATS) has become into as an alternative approach to either, open surgery or video-assisted thoracoscopic surgery. The superiorities of RATS have been reported in series studies, such as intuitive movements, tremor filtration, more degrees of manipulative freedom, motion scaling, and high-definition stereoscopic vision.~However, the currently reported ro...

Summary: Myasthenia gravis (MG) is the autoimmune disorder affecting the neuromuscular junction, characterized by fatigue, which increases gradually through the day. The repetitive nerve stimulation (RNS) remains the key diagnostic test in MG, however its sensitivity, especially in ocular form of MG is not satisfactory. In this study, investigators want to assess the impact of the time of the day on the se...

Summary: The 12 week core training plan designed in this study is based on relevant literature and basketball characteristics. The training plan divides the training difficulty into four levels. The experimental group receives core training with different difficulties in 1-3 weeks, 4-6 weeks, 7-9 weeks and 10-12 weeks respectively.

Summary: This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine t...

Summary: Myasthenia gravis (MG) is a neuromuscular junction (NMJ) transmission disorder mediated by autoantibodies against AChR, MuSK and other autoantigens located at the post synaptic membrane of neuromuscular junction. Presence of autoantibody specific for AChR or MuSK can establish diagnosis in conjunction with clinical presentations. In the guidelines for the diagnosis and treatment of myasthenia grav...

Summary: This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams [mg], 180 mg) in participants with generalized myasthenia gravis (gMG).~Safety will be monitored throughout the study.

Summary: The purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG).~Study details include:~The study duration will be up to 128 weeks (including screening)~Part A (regimen comparison period) - 21 weeks~Part B (extension period) - up to 105 weeks...

Summary: The primary objective is:~To evaluate the effect of pozelimab + cemdisiran on daily functioning that is impacted by signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG)~The secondary objectives of the study are:~To evaluate the effect of pozelimab + cemdisiran (ie, combination) and cemdisiran monotherapy on:~Clinician-assessed signs of myasthenia gravis (MG) and musc...

Summary: This is a multicenter, randomized, double blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tolebrutinib compared with placebo in adult participants aged 18 to 85 years old with moderate-to-severe gMG, who are receiving Standard of Care (SoC). The double-blind (DB) treatment period of 26 weeks will comprise of 7 site visits followed by a 2-year open label extension (O...

Summary: The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.~Trial details include:~The maximum trial duration for each individual participant will be approximately 28 weeks~The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment re...

Summary: This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

Summary: Primary study objective: To verify the efficacy of HBM9161 subcutaneous injection in Chinese patients with gMG